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Abstract
The proteasome is a multicatalytic complex involved in the degradation of polyubiquitinated proteins. Here we review the
clues of a possible involvement of the proteasome in Alzheimer’s disease neuropathology. Thus, we discuss the fact that the
proteasome modulates the intracellular concentrations of presenilins 1 and 2. These two proteins, when mutated, appear
responsible for most of early onset forms of Alzheimer’s disease and this is thought to be due to the exacerbation of the
pathogenic pathway of the maturation of the L-amyloid precursor protein. Controlling presenilins concentrations could have
drastic repercussions on cell physiology as suggested by the fact that proteasome inhibitors drastically potentiate the ‘normal’
or ‘pathogenic’ presenilins phenotype related with LAPP processing. The possibility of considering the proteasome as a
potential target for therapeutic intervention in Alzheimer’s disease is discussed. ß 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
The catabolic processing of proteins mainly in-
volves three degradation systems. A lysosomal set
of acidic hydrolases, a calcium-dependent inactiva-
tion due to calpain activities and an ATP-dependent
degradation thought to occur in the cytoplasm and
triggered by the proteasome. The later enzyme is a
multicatalytic complex that has long been considered
as a proteolytic machinery responsible for ¢nal clear-
ance of ubiquitinated intracellular proteins [1]. More
recently, the design of speci¢c and highly potent
blockers of the proteasome allowed to unmask un-
expected functions of this activity. Particularly, it has
been documented that the proteasome could be re-
sponsible for the degradation of various proteins,
including transcription factors and oncogens, located
in cell compartments distinct from the cytoplasm.
Furthermore, it was proposed that the proteasome
could contribute to the processing of the precursor
of NFUB [2]. Here we gather clues and evidence that
the proteasome could contribute to the Alzheimer’s
disease neuropathology and, more precisely, could
control the physiopathological maturation of the L-
amyloid precursor protein (LAPP) through the mod-
ulation of the intracellular concentration of preseni-
lins.
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2. Ubiquitin- and proteasome-like immunoreactivities
are present in senile plaques
Ubiquitin is a 8.5-kDa polypeptide that is post-
translationally linked to proteins that are usually de-
signed for ¢nal intracellular clearance. It is therefore
not unexpected to ¢nd ubiquitin-like immunoreactiv-
ity and ubiquitinated proteins in the pathological
lesions observed in several neurodegenerative dis-
eases [3,4]. Ubiquitin epitopes have been detected in
the two main lesions characterizing Alzheimer’s dis-
ease, i.e. neuro¢brillary tangles and senile plaques.
Thus, it has been reported that there existed tau-
ubiquitin conjugates [5], that ubiquitin was a compo-
nent of paired helical ¢laments [6] and was detectable
in the neuro¢brillary tangles [7,8]. Ubiquitin-like im-
munoreactivity has also been detected in the senile
plaques of a¡ected AD brains. As stated in the in-
troduction, ubiquitination of proteins is often a cell
mean for triggering proteic ¢nal degradation by the
multicatalytic proteasomal complex. It is therefore of
interest that proteasome-like immunoreactivity has
been immunohistochemically detected in senile pla-
ques and neuro¢brillary tangles of Alzheimer’s dis-
ease brains [9^11].
3. The proteasome displays in vitro secretases-like
activities
Several studies suggested that the proteasome
could behave as a putative secretase. These works,
by means of small peptides as well as chromogenic or
£uorimetric substrates encompassing the sequences
targeted by the various secretases, have led to the
surprising and somewhat incoherent conclusions
that the proteasome could behave as K- [12,13],
L- [14] and Q- [15] secretases. By means of a longer
11-amino acid peptide mimicking the K-secretase
cleaved sequence, we demonstrated that the puri¢ed
proteasome was also able to hydrolyze this peptide
[16]. Interestingly, the cleavage rate was susceptible
to modi¢ed residues [16], some of which were previ-
ously shown to drastically alter the rate of the
K-secretase-derived product of LAPP maturation in
various cell lines [17,18]. Obviously, the in vitro stud-
ies carried out with synthetic peptides did not indi-
cate whether the proteasome could act as secretase(s)
on the natural substrate, i.e. LAPP. In this context,
we expressed and puri¢ed baculoviral recombinant
LAPP751. We established that this protein undergoes
e⁄cient cleavage by puri¢ed proteasome although we
did not establish at which site of the protein break-
down occurred [16].
4. The proteasome is inhibited by, but does not
degrade AL
An interesting study indicated that, in vitro, the
AL peptide could prevent ubiquitin-dependent pro-
tein degradation [19]. This structure^function study
established that the N-terminal domain (AL1^11 or
AL1^16) and the middle sequence(AL25^35) of the
AL peptide were both inhibitory, but that the most
potent inhibitor of ubiquitinated-protein degradation
was AL40 itself [19]. AL neither a¡ected conjugates
formation nor conjugates deubiquitination, indicat-
ing that it more likely prevented a proteolytic step
of the ubiquitin degradation cascade [19]. AL selec-
tively inhibited the chymotrypsin-like activity of the
proteasomal complex [19]. Inhibition of the protea-
some by AL is not due to a simple substrate compe-
tition because AL is not degraded by a fraction pre-
pared from rabbit reticulocytes that is currently used
as a ubiquitin-dependent degradative system [19].
Furthermore, we established that AL does not be-
have as a substrate of puri¢ed proteasome [20]. Gre-
gori et al. showed by scanning transmission electron
microscopy that AL binds to the proteasome and
interacts with the inner catalytic compartment of
the enzyme [21] thereby triggering the protection of
the ubiquitinated proteasomal substrates.
5. Inhibitors of the proteasome a¡ect LAPP
maturation in human cells
In physiological conditions, LAPP undergoes
K- and L/Q-secretase cleavages leading to the forma-
tion of APPK and AL40, respectively. Neuropatho-
logical stigmates corresponding to senile plaques are
thought to derive from the exacerbated production
of AL40 or, alternatively, to the favored formation of
the more aggregable AL42 species (for review see
[22]). The ¢rst clue of a possible involvement of the
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proteasome in the maturation of LAPP came from
our initial observation that long term treatment of
naive HEK293 cells by two proteasome blockers,
Z-IE(Ot-Bu)A-leucinal and lactacystin drastically de-
creased the recovery of secreted APPK in PKC-
stimulated conditions [20]. Later, we con¢rmed this
e¡ect (observed after a 20-h treatment with protea-
some inhibitors), but we further documented the fact
that short-term treatment (6 10 h) of PKC-stimu-
lated HEK293 naive cells with Z-IE(Ot-Bu)A-leuci-
nal and lactacystin leads to increased recovery of
APPK [23]. In addition, we established that protea-
some inhibitors also potentiate the recovery of APPK
observed in basal constitutive secretion conditions
[23]. Concomitantly, proteasome inhibitors augment
the recovery of total AL produced by stably trans-
fected HEK293 cells overexpressing wild-type LAPP
[20]. By means of speci¢c antibodies directed towards
the C-terminal ends of ALs [24], we showed that
proteasome inhibitors drastically increase the recov-
ery of AL40, and to a lesser extent that of AL42 [23].
This agrees well with a subsequent study showing
that proteasome inhibitors increase both AL40 and
AL42 recoveries although these agents did not signif-
icantly a¡ect AL42/AL40 ratio [25].
These data ¢rst indicated that the proteasome does
not display per se any of the secretases activities in
vivo. Second, since proteasome inhibitors increased
both APPK and AL formations in cell cultures, there-
fore exacerbating a ‘normal’ physiological pheno-
type, one could envision the occurrence of an intra-
cellular intermediate involved in the LAPP
maturation, located upstream to both K- and L/Q-
secretases cleavages and behaving as a substrate of
the proteasome.
6. Inhibitors of the proteasome prevent wild-type and
mutated PS1 and PS2 degradation in various cell
systems
Presenilins 1 and 2 (PS1 and PS2) are two analo-
gous transmembrane proteins encoded by genes lo-
cated on chromosomes 14 and 1, respectively [26^28].
These two proteins seem to play a crucial role in the
control of LAPP maturation. We have shown that
the overexpression of wild-type PS1 [29] and PS2
[30] in HEK293 cells leads to an increased secretion
of APPK. This was accompanied by a selective aug-
mentation of the 40 amino-acids long AL species [29].
Thus, it appeared that overexpressing wild-type PS1/
PS2 in£uences LAPP maturation in a similar way to
proteasome inhibitors. Therefore, we questioned
whether PS could correspond to the intracellular in-
termediate behaving as the proteasome substrate,
thereby explaining the pharmacological spectrum of
proteasome inhibitors on the processing of LAPP.
We established, for the ¢rst time, that PS1 undergoes
ubiquitination and behaves as a proteasome sub-
strate [31]. This was later con¢rmed by various stud-
ies indicating that PS1 holoprotein was rapidly bro-
ken down by the proteasome in various cell systems
[32^34] including rat hippocampal organotypic cul-
tures [32]. Similarly, we [30] and others [35] demon-
strated that presenilin 2 is also targeted by the pro-
teasome and rapidly inactivated. It is interesting to
note that a direct interaction of the proteasome with
presenilins was documented by a double hybrid ap-
proach, indicating that a regulatory subunit of the
proteasome ¢rmly interacts with the PSs (Duman-
chin, Campion and Frebourg, personal communica-
tion).
7. Inhibitors of the proteasome potentiate the
wild-type and mutated PS1/2-induced phenotypic
alteration of LAPP maturation
Most early-onset forms of AD are due to muta-
tions borne by PS1/PS2 and are associated with an
abnormal overproduction of AL42 [36]. We demon-
strated that, concomitant to the exacerbation of this
pathogenic LAPP maturation pathway, mutations on
presenilins also trigger drastically reduced secretion
of the physiological catabolite APPK [29,30]. Inter-
estingly, the proteasome displays similar catabolic
activity towards various PS1 and PS2 proteins bear-
ing pathogenic missense mutations [30,31].
If the control of the levels of PS and their mutated
analogs modulates their function, blocking their deg-
radation and thereby increasing their intracellular
concentrations should lead to an exacerbation of
their ‘normal’ or ‘pathogenic’ phenotype. In this con-
text, we examined the e¡ect of proteasome inhibitors
on the processing of LAPP by cells overexpressing
wild-type and mutated PS1 or PS2. HEK293 cells
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expressing wild-type PS1 produce higher amount of
APPK upon inhibitor treatment. Proteasome inhibi-
tors also drastically potentiated the selective increase
in AL42 secretion observed with mutated PS1-ex-
pressing cells [31]. Similarly, we recently established
that proteasome inhibitors increase the wild-type
PS2-mediated production of APPK. In contrast,
these inhibitors amplify the decrease in APPK recov-
ery observed with mutated PS2-expressing cells [30].
8. Inhibitors of the proteasome prevent the
degradation of the C-terminal maturation products
of presenilins 1 and 2 in human cells and potentiate
their phenotypes
Presenilins 1 and 2 are maturated proteins that are
converted into 18 and 28 kDa C- and N-terminal
fragments, respectively, by a still unidenti¢ed ‘prese-
nilinase’ [36^38]. Some lines of evidence indicate that
the PS maturation fragments are biologically active
[39]. We recently established that overexpression of
the C-terminal (CTF) fragments of PS1 and PS2 trig-
gers increased production of APPK and AL in
HEK293 cells [40]. Furthermore, we established
that these CTF fragments behave as substrates of
the proteasome [40]. Finally, we showed that the
treatment of transfected cells overexpressing CTF-
PS1/PS2 with proteasome inhibitors further potenti-
ates the CTF-mediated secretions of APPK and AL
[40].
Altogether, these data indicated that the protea-
some acts as a regulator of LAPP maturation via
the control of intracellular concentrations of PS1/2
holoproteins and/or their maturation fragments,
thereby modulating both K-and L/Q-secretase-derived
LAPP metabolites (Fig. 1). The ability of the protea-
some to target proteins located in the endoplasmic
reticulum, a cell compartment where the bulk of PS
is present and where their maturation occurs, further
reinforces the physiological importance of the pro-
teasome in PS physiology.
Fig. 1. The proteasome degrades PS1, PS2, mutated PS1/PS2 (FAD-linked PS1/PS2) and their presenilinase (PSase)-derived C-terminal
fragments (CTF/NTF-PS1/PS2) upstream to their ‘biological’ interaction with LAPP, thereby modulating both K- and L/Q-secretases
derived products APPK and AL40/42, respectively. PS1/PS2 and CTF-PS1/PS2 contribute to the production of APPK and AL40, the
production of which is increased by proteasome inhibitors (plain yellow arrows, route 1). Mutated PS1/PS2 secrete lower amounts of
APPK and selectively increase AL42 recovery. Proteasome inhibitors further lower APPK and potentiate AL42 secretions by FAD-
linked PS1/PS2 (blue line, route 2). Whether AL could trigger an ampli¢cation of its own production by inhibition of the proteasome
(yellow dashed line) and subsequent protection of PS is still a matter of speculation. It is hypothesized that, by accelerating the degra-
dation of wild-type and mutated PS or their CTFs, proteasome activators should hopefully lead to decreased recovery of AL40 or
AL42 in both sporadic and PS-related genetic forms of AD.
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9. Proteasome activators: a potential therapeutic
approach?
As outlined above, inhibitors of the proteasome
enhance AL40 secretion in the case of cells expressing
wild-type PS1/2. This e¡ect is also observed in cells
displaying an endogenous content of ‘wild-type’ PSs.
When cells express mutated PS1/2, the formation of
AL42 is exacerbated. It is therefore possible to envi-
sion that activators of the proteasome, would en-
hance wild-type or mutated PS degradation, thereby
lowering the intracellular concentration of these pro-
teins and reducing AL40/42 secretion. Such strategy
would therefore theoretically stand for both sporadic
and genetic forms of Alzheimer’s disease. As far as
the amyloidogenic hypothesis for this neurodegener-
ative disease is privileged, this could be an essential
route to slow down or prevent the development of
senile plaques. It should be noted that several endog-
enous activators of the proteasome have been re-
ported, indicating that this multicatalytic complex
is a highly controlled enzymatic machinery that can
be upregulated. Whether putative improvements in
AD evolution would be balanced by side e¡ects of
the proteasome inhibitors obviously would remain a
major concern.
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